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Abstract: Four spontaneously derived serologically distinct classes of 
mutants of the Paramecium bursaria chlorella virus (PBCV-1) were iso-
lated using polydonal antiserum prepared against either intact PBCV-1 
or PBCV-1-derived serotypes. The oligosaccharide(s) of the viral major 
capsid protein and two minor glycoproteins determined virus serolog-
ical specificity. Normally, viral glycoproteins arise from host-specific 
glycosylation of viral proteins; the glycan portion can be altered only 
by growing the virus on another host or by mutations in glycosylation 
sites of the viral protein. Neither mechanism explains the changes in 
the glycan(s) of the PBCV-1 major capsid protein because all of the vi-
ruses were grown in the same host alga and the predicted amino acid 
sequence of the major capsid protein was identical in the PBCV-1 se-
rotypes. PBCV-1 antiserum resistance is best explained by viral muta-
tions that block specific steps in glycosylation, possibly by inactivating 
glycosyltransferases. 
Abbreviations: PBCV-1, Paramecium bursaria chlorella virus; TFMSA, 
trifluoromethanesulfonic acid.
Paramecium bursaria chlorella virus (PBCV-1) is a large (≈190 
nm in diameter) polyhedral plaque-forming virus that repli-
cates in certain unicellular eukaryotic exsymbiotic Chlorella-
like green algae (1). The PBCV-1 genome is a linear nonper-
muted 333-kb double-stranded DNA with covalently closed 
hairpin ends (2, 3). PBCV-1 contains at least 50 proteins and 
a lipid component located inside the capsid shell (4). The ma-
jor capsid protein (Vp54) of PBCV-1 is one of four proteins lo-
cated on the viral surface and is one of three glycosylated vi-
ral proteins. PBCV-1 and its related viruses have recently been 
assigned to a virus family, named Phycodnaviridae (5). Addi-
tional features of these viruses have been reviewed (6).
Chase et al. (7) showed that chlorella viruses exclude one 
another during dual inoculation of the host. For these studies 
we isolated a spontaneous mutant of PBCV-1, named EPA-1, 
which was resistant to PBCV-1 polyclonal antiserum (dilution 
of 1:4). This antiserum completely inhibited PBCV-1 infection 
even at a dilution of 1:1000. Polyclonal antiserum prepared 
against EPA-1 inhibited EPA-1 infection (dilution of 1:1000) 
but not PBCV-1 infection (dilution of 1:4). In this study we 
have addressed two questions: (i) Can additional PBCV-1 se-
rotypes be isolated using polyclonal antisera to intact viruses? 
(ii) What virus component determines antiserum resistance? 
We have found four PBCV-1 serotypes and discovered that the 
antisera react primarily with oligosaccharide(s) attached to the 
major capsid protein plus two minor glycoproteins. More im-
portantly, in contrast to normal virus protein glycosylation, 
the virus rather than the host dictates glycosylation specificity.
Materials And Methods
Culture Conditions. The procedures for producing, puri-
fying, and “plaquing” the viruses and the growth of the host 
alga (Chlorella NC64A) on MBBM medium have been de-
scribed (1, 8). Virus glycoproteins were specifically labeled by 
adding 100 μCi of D-[6-3H]-galactose (1 Ci = 37 GBq) to 1 ml of 
cells (6 x 108 cells per ml) 30 min after virus infection. After ly-
sis, the labeled virions were isolated by standard procedures.
Isolation of PBCV-1 Serotypes. Spontaneous serotype 
mutants of PBCV-1 or its relatives were isolated by incubat-
ing 1 x 109 plaque-forming units (pfu) of virus with virus poly-
clonal antiserum (1:10 dilution) for 30 min, removing aggluti-
nated virus by centrifuging (3000 × g) for 5 min, and titering 
the supernatant. Typically 500–1,000 antiserum-resistant vi-
ruses were obtained from 109 pfu of parent virus and >95% of 
these plaques consisted of mutant viruses that were insensitive 
to the original virus antiserum; i.e., <5% of the plaques were 
from parent viruses that escaped antiserum precipitation.
Polyacrylamide Gel Electrophoresis of Virus Proteins and 
Western Blot Analysis. Purified viruses [0.06 A260 unit in 10 
μl of 50 mM Tris HCl (pH 7.8)] were mixed with 10 μl of 2× 
dissociation buffer [125 mM Tris HCl, pH 8.4/3% (wt/vol) 
SDS/20% (vol/vol) glycerol/0.1 M dithiothreitol/0.08% bro-
mophenol blue] and heated to 65°C for 1 hr or 100°C for 5 min. 
Samples were electrophoresed on a linear 6–18% polyacryl-
amide gradient slab gel with a 4% stacking gel at 70 V for 16 hr 
in the buffer system of Laemmli (9). Proteins were visualized 
by silver staining (10).
Proteins were transferred to nitrocellulose sheets at a con-
stant current flux of 1 mA/cm2 for 5 hr at room temperature 
in the buffer system described by Towbin et al. (11) with 20% 
(vol/vol) methanol. The sheets were washed for 5 min in 1× 
TBST buffer (10 mM Tris-HCl, pH 8.0/150 mM NaCl/0.05% 
Tween 20) and incubated for 1 hr in TBST with 5% (wt/vol) 
nonfat dry milk (blocking solution) containing primary anti-
serum diluted 1:750 to 1:1000. The sheets were washed three 
times in TBST, incubated for 1 hr at room temperature with 
goat anti-rabbit IgG-conjugated alkaline phosphatase (1:2000 
dilution) in blocking solution, washed three times in TBST, 
and incubated in alkaline phosphate (AP) buffer (100 mM Tris-
HCl, pH 9.5/100 mM NaCl/5 mM MgCl2) for 5 min. Color 
was developed by incubating the sheets in 15 ml of AP buffer 
containing 40 μl of nitroblue tetrazolium (112 mg dissolved in 
1 ml of N,N-dimethyl formamide and 0.5 ml of water) and 32 
μl of 5-bromo-4-chloro-3-indolyl phosphate (100 mg dissolved 
in 2 ml of N,N-dimethyl formamide) (12). Color development 
was stopped by placing the sheets in distilled water.
Isolation of Virus Major Capsid Protein. Viral glycoproteins, 
including the major capsid protein Vp54, were dissociated from 
virions by incubating purified virus in 50 mM Tris HCl (pH 7.8) 
at 65°C for 1 hr and then centrifuging at 10,000 × g for 10 min. 
At least 80% of the supernatant protein consisted of Vp54. The 
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protein was dried, resuspended in dissociation buffer, and elec-
trophoresed on preparative polyacrylamide gels as described 
above. After electrophoresis the major capsid protein was visu-
alized by soaking the gel in 4 M sodium acetate (13). The major 
capsid protein region was excised with a razor blade and cut into 
small blocks, and protein was electroeluted and concentrated us-
ing an ISCO electrophoretic concentrator. The concentrator con-
tained 10 mM NH4HCO3/0.1% SDS in the sample cup and 50 
mM NH4HCO3/0.1% SDS in the buffer chambers. After elution, 
protein was precipitated with 5 vol of acetone.
Deglycosylation. The major capsid proteins were degly-
cosylated with trifluoromethanesulfonic acid (TFMSA) by a 
modification of the procedure of Edge et al. (14). Virus or puri-
fied major capsid proteins were suspended in 50 μl of TFMSA 
and 25 μl of anisole and incubated on ice for 1-3 hr. The reac-
tion was stopped by adding 125 μl of N-ethylmorpholine (15). 
Protein was recovered by acetone precipitation and immedi-
ately analyzed on SDS/polyacrylamide gels.
Sugar Analysis. Equal volumes of 65°C solubilized viral 
proteins (see above) were mixed with equal volumes of 4 M 
trifluoroacetic acid and hydrolyzed for 4 hr at 100°C. The sam-
ples were cooled and the acid was evaporated. The samples 
were suspended in deionized water and passed through an 
OnGuard A cartridge (Dionex). Monosaccharides were bound 
to a Dionex Carbopac PA1 anion-exchange column and eluted 
for 35 min with isocratic 2.5 mM NaOH (16) by procedures 
recommended by Dionex. Peaks were integrated and plotted 
on a Dionex 4400 integrater. The internal standard was 2-de-
oxyglucose. Retention times and peak areas were compared to 
standards including fucose, galactosamine, galactose, glucos-
amine, glucose, xylose, arabinose, rhamnose, and mannose.
Other Procedures. Nitrocellulose sheets containing virus 
proteins were mildly oxidized with periodic acid as described 
by Woodward et al. (17). Polyclonal antiserum to the viruses 
was raised against purified viruses as described (18). DNA 
was isolated from the purified viruses as described (19) and 
treated with restriction endonucleases according to suppliers’ 
protocols. DNA was sequenced in both directions by the pro-
cedure of Sanger et al. (20), as modified by Tabor and Rich-
ardson (21), using a Sequenase (Version 2.0) kit from United 
States Biochemical.
Results
Isolation of PBCV-1 Serotypes. We have isolated (7) a mu-
tant of PBCV-1, EPA-1, that was resistant to PBCV-1 poly-
clonal antiserum. Polyclonal antiserum prepared against EPA-
1 inhibited EPA-1 infection (dilution of 1:1000) but not PBCV-1 
infection even at high antiserum concentrations (7). Addi-
tional spontaneously derived PBCV-1 serotypes were selected 
with polyclonal antisera prepared against either PBCV-1 or se-
rotypes derived from PBCV-1. Four serologically distinct mu-
tant classes (summarized in Table 1) of PBCV-1 were obtained: 
P91; P31 and EPA-1; P41 and E11; and P100. Virus E11 arose 
from EPA-1 and virus P100 arose from P31; presumably, these 
two viruses contain two independent mutations. Each of these 
viruses was stable and polyclonal antiserum made to one of 
the serotypes completely inhibited infection by members of 
the same serotype (at a dilution of 1:1000) but had no effect at 
a 1:4 dilution on the other serotypes.
The polyclonal antisera inhibit homologous virus infection 
by agglutination. Antisera treated with papain, which pro-
duces monovalent Fab fragments (22), did not inhibit homolo-
gous virus infection. However, adding goat anti-rabbit IgG to 
Fab-treated virus inhibited virus infection. 
Virus DNA. DNA from each of the viruses was digested 
with several DNA restriction endonucleases and analyzed on 
agarose gels. Identical restriction fragments were observed with 
DNA from PBCV-1, P91, P31, P41, and P100 with each of the re-
striction endonucleases. A single common BamHI fragment and 
a single Hha I fragment (Figure 1) were altered in DNA from 
EPA-1 and E11. The altered BamHI fragment (B8a) is located at 
positions 55-66 on the physical map of PBCV-1 (6). This suggests 
that EPA-1 arose from a deletion and that P91, P31, P41, and 
P100 arose from either point mutations or very small deletions 
in separate PBCV-1 genes. E11 likely arose from a point muta-
tion in EPA-1, possibly in the same gene that produced P41.
Protein Patterns of the PBCV-1 Serotypes. Each of the vi-
ruses was heated either to 65°C for 1 hr or 100°C for 5 min 
in dissociation buffer and the proteins were electrophoresed 
on SDS/polyacrylamide gels. The PBCV-1 major capsid pro-
tein (Vp54), which makes up ≈40% of the total virus protein, 
migrates as a dimer when heated to 65°C and as a monomer 
when heated to 100°C (4, 23). As shown in Figure 2A, both the 
dimer and monomer forms of the major capsid protein of each 
Table 1. Virus PBCV-1 serotypes
                                            Antiserum agglutination
Virus            Source         PBCV-1      P91       EPA-1        P41         P100
PBCV-1  — Yes  No  No  No  No
P91  PBCV-1  No  Yes  No  No  No
EPA-1  PBCV-1  No  No  Yes  No  No
P31  PBCV-1  No  No  Yes  No  No
P41  PBCV-1  No  No  No  Yes  No
E11  EPA-1  No  No  No  Yes  No
P100  P31  No  No  No  No  Yes
Polyclonal antiserum was prepared against PBCV-1, P91, EPA-1, P41, 
and P100 viruses. Yes = a 1:1000 dilution of the indicated antiserum 
indicated agglutinated the virus; No = a 1:4 dilution of the antiserum 
indicated did not agglutinate the virus.
Figure 1. Digestion patterns of PBCV-1 (lane 1), P91 (lane 2), EPA-1 
(lane 3), P31 (lane 4), P41 (lane 5), E11 (lane 6), and P100 (lane 7) viral 
DNA. The DNAs were digested with BamHI (A) or Hha I (B). A single 
BamHI fragment and a single Hha I fragment (arrow) were altered in 
the DNAs from EPA-1 and E11. 
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mutant migrated faster than the major capsid protein of its 
parent. Furthermore, the major capsid proteins from the sero-
types migrated differently from one another, whereas the ma-
jor capsid protein from viruses in the same serotypes migrated 
at identical rates. The viruses PBCV-1, P91, EPA-1 and P31, P41 
and E11, and P100 are arranged in Figure 2A by decreasing size 
of the major capsid protein. The virus mutations that affected 
the migration of the major capsid protein also affected the mi-
gration of the other two viral glycoproteins (Figure 2C). Like 
the major capsid protein, these two glycoproteins, each being 
1–2% of the total virus protein, migrated faster than the paren-
tal glycoproteins. Other proteins were unaffected. The change 
in the glycoproteins in the serotypes was consistent with the 
glycoprotein determining serological specificity of the viruses.
This possibility was supported by Western blot analysis. The 
virus major capsid proteins (Figure 2B) and the other two minor 
virus glycoproteins reacted strongly only with homologous an-
tiserum. Each antiserum also reacted, but to a much lesser ex-
tent, with other virus proteins, presumably reflecting epitopes 
exposed by disruption of virus particles during immunization. 
None of the virus antisera reacted with host chlorella proteins.
The Primary Epitope Is Oligosaccharide(s). The epitope(s) 
responsible for the serological specificity could be either the 
carbohydrate or polypeptide portion of the major capsid pro-
tein. The major capsid proteins from all the viruses comigrated 
with an apparent molecular mass of 49 kDa in SDS/polyacryl-
amide gels after deglycosylation with TFMSA (Figure 2A). The 
value of 49 kDa agrees with the predicted molecular mass of 
48.2 kDa for the PBCV-1 major capsid protein derived from se-
quencing its gene (23). The apparent identity of the deglyco-
sylated major capsid proteins from all the virus serotypes indi-
cates that the protein size differences reflect differences in the 
carbohydrate moieties. Three experiments confirmed this con-
clusion. (i) Deglycosylation abolished the specific reaction of 
the major capsid proteins with homologous antiserum. (ii) Pe-
riodic acid treatment of virus proteins after transfer to nitrocel-
lulose, which destroys carbohydrate epitopes of glycoproteins 
(17), reduced the reaction of the antisera with the major capsid 
proteins, but not with the other virus proteins. (iii) The ratios 
of six and/or seven sugars (fucose, galactose, glucose, xylose, 
mannose, and arabinose and/or rhamnose) associated with the 
viral glycoproteins of PBCV-1 and the mutants varied in a pre-
dictable manner that was related to their serotypes and the ap-
parent size of the glycoproteins (Table 2). Thus we conclude 
that the oligosaccharide(s) attached to the major capsid pro-
teins determines the serological differences among the viruses.
Sequence ofthe Major Capsid Protein Gene. The ma-
jor capsid protein gene from the parent virus PBCV-1 was re-
cently isolated and sequenced; the Vp54 gene is located at po-
sitions 209–211 on the PBCV-1 physical map (23). An amino 
acid change(s) in the major capsid protein could alter a glyco-
sylation site(s) in the protein leading to oligosaccharide(s) dif-
ferences among the PBCV-1 serotypes. To examine this possi-
bility, we cloned and sequenced the major capsid protein gene 
from viruses EPA-1 and P100. The base sequence and, hence, 
the predicted amino acid sequence for the major capsid pro-
teins from both mutants was identical to that of PBCV-1. 
Discussion
Four spontaneously derived serologically distinct classes 
of mutants of the chlorella virus PBCV-1 were isolated us-
ing polyclonal antiserum made against either PBCV-1 or the 
Figure 2. (A) SDS/PAGE of the major capsid protein from PBCV-1, P91, EPA-1, P31, P41, E11, and P100 viruses. The samples were heated to 65°C 
for 1 hr (dimer), 100°C for 5 min (monomer), or deglycosylated with TFMSA prior to electrophoresis. (B) Immunoblot of the major capsid protein 
from PBCV-1, P91, EPA-1, P31, P41, E11, and P100. The blots were treated with antiserum (Ab) against PBCV-1, P91, EPA-1, P41, or P100 as indi-
cated. Note: the major capsid proteins reacted primarily with homologous antiserum. (C) Migration of [3H] galactose-labeled glycoproteins from 
PBCV-1, P91, P31, P41, and P100 viruses. The samples were heated at 100°C for 5 min prior to electrophoresis. Note: the virus mutations that affect 
the migration of the major capsid protein also affect the migration of the two minor viral glycoproteins. Molecular masses in kDa are shown.
Table 2. Sugar composition of the glycoproteins from PBCV-1  
serotypes
                                             Relative sugar content
Sugar             PBCV-1    P91      EPA-1      P31       P41        E11      P100
Fucose  0.69  0.73  0.88  0.81  0.78  0.83  0.61
Ara/Rham  1.57  1.24  0.64  0.65  0.65  0.65  0.19
Galactose  1.02  0.97  1.02  1.03  0.99  0.97  0.91
Glucose  1.00  1.00  1.00  1.00  1.00  1.00  1.00
Xylose  1.58  1.47  1.59  1.57  0.88  0.77  0.60
Mannose  1.02  0.70  0.14  0.17  0.24  0.15  0.12
Values are normalized to that of glucose. Note: fucose and galactose 
also do not change. The mutants are arranged so that the major capsid 
protein decreases in size from PBCV-1 to P100. Viruses EPA-1 and P31 
and viruses P41 and E11 are serologically similar even though they are 
separate isolates. Viruses P91, EPA-1, P31, and P41 are derived from 
PBCV-1; virus E11 is derived from EPA-1; and virus P100 is from P31. 
Ara/Rham =  arabinose/rhamnose.
Ev i d E n c E f o r v i r u s-E n c o d E d g l y c o s y l a t i o n s p E c i f i c i t y   3843
serotypes. Virus major capsid protein and two minor vi-
ral glycoproteins (apparent molecular masses of 280 and 270 
kDa from PBCV-1), from the serotypes migrated in a distinc-
tive but predictable fashion on SDS/polyacrylamide gels (Fig-
ure 2C), whereas the remaining viral proteins comigrated. 
The polyclonal antisera recognize oligosaccharide epitopes 
on the major capsid protein. The two other viral glycopro-
teins share these epitopes and are affected in parallel by an-
tiserum-resistance mutations. By these criteria the oligosac-
charides of the three glycoproteins are indistinguishable.
Glycoproteins are important structural components of 
many viruses (24). Usually the carbohydrate moieties of vi-
rus glycoproteins are added in the rough endoplasmic reticu-
lum and Golgi by host-encoded glycosyltransferases (24). Vi-
rus glycoproteins are then transported to the cell membrane 
and viruses acquire their glycoprotein(s) by budding through 
the host membrane as they are released from the cell. Conse-
quently, changes in the glycan portion of virus glycoproteins 
can occur (i) by varying the host [e.g., herpesvirus (25, 26) and 
influenza virus (27, 28)] or (ii) by altering an amino acid se-
quence to create or destroy a glycosylation site [e.g., vesicu-
lar stomatitis virus (29)]. However, neither of these mecha-
nisms explain the altered glycan(s) in the major capsid protein 
of PBCV-1: (i) All viruses are grown in the same host, and (ii) 
the predicted amino acid sequences of the major capsid pro-
tein from PBCV-1 and two of its serotypes, EPA-1 and P100, 
are identical. Furthermore, the PBCV-1 major capsid protein 
and the other two virus glycoproteins are added to the virus 
inside the cell since intact infectious PBCV-1 particles accumu-
late within the cell prior to virus release (1).
The pattern of antiserum-resistant mutants suggests that 
PBCV-1 influences at least four steps of a common glycosyl-
ation pathway. Because mutant glycoproteins migrate faster 
on SDS/polyacrylamide gels than those of the parents, it is un-
likely that the mutation affects a glycosidase cleavage pathway 
since this would produce a larger oligosaccharide. Three other 
observations are consistent with the glycosylation hypothesis: 
(i) Each of the four virus serotypes appear to arise from sepa-
rate single mutations in the PBCV-1 genome. Although more 
sophisticated genetic analyses are required to determine mu-
tation frequencies, the serotypic variants are present at ≈1 per 
106 virus particles. This number is consistent with a single mu-
tation. (ii) The major capsid protein of PBCV-1 and the sero-
types contains six and/or seven sugars (fucose, galactose, glu-
cose, xylose, mannose, and arabinose and/or rhamnose) that 
vary in a predictable manner that is related to their serotype 
and the migration of the major capsid protein (Table 2). (iii) 
The viral antisera did not react with host proteins.
A model consistent with the data is presented in Figure 
3. The PBCV-1 major capsid protein has one or more glycan 
components containing sugars in sequential order: sugar A–
sugar B–sugar C–sugar D–sugar E. Sugar A is attached to the 
amino acid and the terminal sugar E serves as the PBCV-1 epi-
tope. Virus P91 contains a mutation that prevents the addition 
of sugar E; consequently, terminal sugar D serves as the P91 
epitope. The other virus serotypes result from mutations that 
eliminate additional terminal sugars; in each case the terminal 
sugar serves as the epitope. Two variations of the model are 
also consistent with the data. (i) The linkage of the terminal 
sugar differs with each serotype or (ii) the sugars represented 
as A, B, C, D, and E consist of more than one sugar.
This simple testable model explains the specificity of each 
antiserum, the different carbohydrate contents of the major 
capsid proteins of each serotype, and the mobility differences 
of the major capsid proteins on SDS/polyacrylamide gels. The 
model also predicts that the gene for each enzyme can be in-
dependently mutated and that genetic crosses between appro-
priate serotypes should produce wild-type viruses. It will also 
be important to determine the intracellular location of PBCV-
1 protein glycosylation. The proteins could be glycosylated 
via the conventional rough endoplasmic reticulum and Golgi 
pathway, possibly using virus-encoded glycosyltransferases. 
If so, the virus glycoproteins need a signal for targeting them 
to the virus cytoplasmic assembly centers. Alternatively, viral 
glycosylation could be independent of the traditional rough 
endoplasmic reticulum and Golgi system. In this regard, evi-
dence is accumulating for nuclear and cytoplasmic glycosyl-
ation of some cell proteins (for review, see reference 30).
In summary, chlorella virus PBCV-1 has an interesting and 
apparently unusual method for glycosylating its glycoproteins. 
Regardless of whether PBCV-1 encodes its own glycosylating 
enzymes or somehow manipulates host enzymes, the mecha-
nism adds still another function encoded by PBCV-1. The chlo-
rella viruses are unusual in that they code for DNA site-specific 
(restriction) endonucleases and DNA methyltransferases (6).
We thank Dwight Burbank for technical assistance, Russ Meints 
and Mike Graves for advice on cloning the major capsid protein gene 
from the PBCV-1 mutants, Ken Nickerson for advice on the sugar 
analyses, and Peter Albersheim and Gary Hart for helpful discus-
sions. This investigation was supported, in part, by Public Health Ser-
vice Grant GM-32441 from the National Institute of General Medical 
Sciences. This manuscript is Journal Series No. 10152, Agricultural Re-
search Division, University of Nebraska. 
References
1. Van Etten, J. L., Burbank, D. E., Xia, Y. & Meints, R. H. (1983) 
Virology 126, 117-125.
2. Girton, L. E. & Van Etten, J. L. (1987) Plant Mol. Biol. 9, 
247-257.
3. Rohozinski, J., Girton, L. E. & Van Etten, J. L. (1989) Virology 
168, 363-369.
4. Skrdla, M. P., Burbank, D. E., Xia, Y., Meints, R. H. & Van 
Etten, J. L. (1984) Virology 135, 308-315.
Figure 3. Proposed model for the structure of the oligosaccharide moi-
eties attached to the viral major capsid protein. In this model, sugars 
B-E may represent monosaccharides, oligosaccharides, or different 
types of linkages. Enzymes I-IV are responsible for the transfer of sug-
ars B-E to preexisting substrates. Presumably, the sugars can only be 
added in the order presented so that, e.g., a defect in enzyme I pre-
vents the addition of any sugars onto sugar A. PBCV-1 serotypes that 
could be missing an enzyme activity are listed on the left.
3844 i-n. Wa n g E t a l.  i n Pr o c. Na t l.  ac a d. Sc i .  USa  90 (1993) 
5. Francki, R. I. B., Fauquet, C. M., Knudson, D. L. & Brown, F. 
(1991) Arch. Virol., Suppl. 2, 137-139.
6. Van Etten, J. L., Lane, L. C. & Meints, R. H. (1991) Microbiol. 
Rev. 55, 586-620.
7. Chase, T. E., Nelson, J. A., Burbank, D. E. & Van Etten, J. L. 
(1989) J. Gen. Virol. 70, 1829-1836.
8. Van Etten, J. L., Burbank, D. E., Kuczmarski, D. & Meints, R. 
H. (1983) Science 219, 994-996.
9. Laemmli, U. K. (1970) Nature (London) 227, 680-685.
10. Monroy, A. F. & Schwartzbach, S. D. (1983) Planta 158, 
249-258.
11. Towbin, H., Staehelin, T. & Gordon, J. (1979) Proc. Natl. 
Acad. Sci. USA 76, 4350-4354.
12. Blake, M. S., Johnston, K. H., Russell-Jones, G. J. & 
Gotschlich, E. C. (1984) Anal. Biochem. 136, 175-179.
13. Higgins, R. C. & Dahmus, M. E. (1979) Anal. Biochem. 93, 
257-260.
14. Edge, A. S. B., Faltynek, C. R., Hof, L., Reichert, L. E. & We-
ber, P. (1981) Anal. Biochem. 118, 131-137.
15. Skopp, R. N. & Lane, L. C. (1988) Appl. Theor. Electrophore-
sis 1, 61-64.
16. Hardy, M. R., Townsend, R. R. & Lee, Y. C. (1988) Anal. Bio-
chem. 170, 54-62.
17. Woodward, M. P., Young, W. W. & Bloodgood, R. A. (1985) 
J. Immunol. Methods 78, 143-153.
18. Van Etten, J. L., Meints, R. H., Kuczmarski, D., Burbank, D. 
E. & Lee, K. (1982) Proc. Natl. Acad. Sci. USA 79, 3867-3871.
19. Van Etten, J. L., Meints, R. H., Burbank, D. E., Kuczmar-
ski, D., Cuppels, D. A. & Lane, L. C. (1981) Virology 113, 
704- 711.
20. Sanger, R., Nicklen, S. & Coulson, A. R. (1977) Proc. Natl. 
Acad. Sci. USA 74, 5463-5467.
21. Tabor, S. & Richardson, C. C. (1987) Proc. Natl. Acad. Sci. 
USA 84, 4767-4771.
22. Porter, R. R. (1959) Biochem. J. 73, 119-126.
23. Graves, M. V. & Meints, R. H. (1992) Virology 188, 198-207.
24. Schlesinger, M. J. & Schlesinger, S. (1987) Adv. Virus Res. 
33, 1-44.
25. Lundstrom, M., Jeansson, S. & Olofsson, S. (1987) Virology 
161, 395-402.
26. Lundstrom, M., Olofsson, S., Jeansson, S., Lycke, E., 
Datema, R. & Mansson, J. E. (1987) Virology 161, 385-394.
27. Nakamura, K. & Compans, R. W. (1979) Virology 95, 8-23.
28. Deom, C. M. & Schulze, I. T. (1985) J. Biol. Chem. 260, 
14771-14774.
29. Luo, L., Li, Y., Snyder, R. M. & Wagner, R. R. (1990) Virol-
ogy 174, 70-78.
30. Hart, G. W., Haltiwanger, R. S., Holt, G. D. & Kelly, W. G. 
(1989) Annu. Rev. Biochem. 58, 841-874.
